Alan Roth is an experienced leader in health sciences integrating basic research, investment management/capital markets, strategic consultancy and executive operations. His career includes New Lead Discovery at Merck & Co., McKinsey, Commerzbank Asset Management ($140bn AUM) and co-founding CEO of the biotechnology company Chiral Quest in chiral pharmaceuticals. He is currently the CEO of Oxford Drug Design, an Oxford University spinout in precision oncology therapeutics led by pioneering AI. Alan is a Royal Society Entrepreneur in Residence and Visiting Lecturer at the University of Oxford, Director at Fitzroy Partners, a Guest Professor at the University of Cologne, the University of Tianjin, and the US Military Academy, West Point.